95 related articles for article (PubMed ID: 22064349)
1. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
Mol Cancer; 2014 May; 13():116. PubMed ID: 24885082
[TBL] [Abstract][Full Text] [Related]
3. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi Y; Goyama S; Liu X; Tamura M; Asada S; Tanaka Y; Fukuyama T; Wunderlich M; O'Brien E; Mizukawa B; Yamazaki S; Matsumoto A; Yamasaki S; Shibata T; Matsuda K; Sashida G; Takizawa H; Kitamura T
Nat Commun; 2019 Oct; 10(1):4869. PubMed ID: 31653912
[TBL] [Abstract][Full Text] [Related]
4. Enhanced
Nishida Y; Ishizawa J; Ayoub E; Montoya RH; Ostermann LB; Muftuoglu M; Ruvolo VR; Patsilevas T; Scruggs DA; Khazaei S; Mak PY; Tao W; Carter BZ; Boettcher S; Ebert BL; Daver NG; Konopleva M; Seki T; Kojima K; Andreeff M
Sci Adv; 2023 Dec; 9(48):eadh1436. PubMed ID: 38019903
[TBL] [Abstract][Full Text] [Related]
5. Natural HDAC-1/8 inhibitor baicalein exerts therapeutic effect in CBF-AML.
Yu X; Li H; Hu P; Qing Y; Wang X; Zhu M; Wang H; Wang Z; Xu J; Guo Q; Hui H
Clin Transl Med; 2020 Aug; 10(4):e154. PubMed ID: 32898337
[TBL] [Abstract][Full Text] [Related]
6. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ; Mak PY; Muftuoglu M; Tao W; Ke B; Pei J; Bedoy AD; Ostermann LB; Nishida Y; Isgandarova S; Sobieski M; Nguyen N; Powell RT; Martinez-Moczygemba M; Stephan C; Basyal M; Pemmaraju N; Boettcher S; Ebert BL; Shpall EJ; Wallner B; Morgan RA; Karras GI; Moll UM; Andreeff M
Blood; 2023 Sep; 142(12):1056-1070. PubMed ID: 37339579
[TBL] [Abstract][Full Text] [Related]
7. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho JNHG; Schmidt D; Lowinus T; Ryoo J; Dopfer EP; Gonzalo Núñez N; Costa-Pereira S; Toffalori C; Punta M; Fetsch V; Wertheimer T; Rittmann MC; Braun LM; Follo M; Briere C; Vinnakota JM; Langenbach M; Koppers F; Shoumariyeh K; Engel H; Rückert T; Märklin M; Holzmayer S; Illert AL; Magon F; Andrieux G; Duquesne S; Pfeifer D; Staniek J; Rizzi M; Miething C; Köhler N; Duyster J; Menssen HD; Boerries M; Buescher JM; Cabezas-Wallscheid N; Blazar BR; Apostolova P; Vago L; Pearce EL; Becher B; Zeiser R
Blood; 2022 Sep; 140(10):1167-1181. PubMed ID: 35853161
[TBL] [Abstract][Full Text] [Related]
8. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice.
Pourebrahim R; Montoya RH; Akiyama H; Ostermann L; Khazaei S; Muftuoglu M; Baran N; Zhao R; Lesluyes T; Liu B; Khoury JD; Gagea M; Van Loo P; Andreeff M
Cell Rep Med; 2024 May; 5(5):101558. PubMed ID: 38733986
[TBL] [Abstract][Full Text] [Related]
9. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
Khurana A; Shafer DA
Onco Targets Ther; 2019; 12():2903-2910. PubMed ID: 31289443
[TBL] [Abstract][Full Text] [Related]
10. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
Boudreaux SP; Duren RP; Call SG; Nguyen L; Freire PR; Narayanan P; Redell MS; Conneely OM
Leukemia; 2019 Jan; 33(1):52-63. PubMed ID: 29884904
[TBL] [Abstract][Full Text] [Related]
11. Targeting inhibition of TCTP could inhibit proliferation and induce apoptosis in AML cells.
Xia D; Xu GP; Zhang YT; Yan WW; Pan XR; Tong JH
Cell Signal; 2024 May; 117():111074. PubMed ID: 38309549
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
Fredly H; Gjertsen BT; Bruserud O
Clin Epigenetics; 2013 Jul; 5(1):12. PubMed ID: 23898968
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
Man CH; Lam W; Dang CC; Zeng XY; Zheng LC; Chan NN; Ng KL; Chan KC; Kwok TH; Ng TC; Leung WY; Huen MS; Wong CC; So CWE; Dou Z; Goyama S; Bray MR; Mak TW; Leung AY
Blood; 2023 Dec; 142(23):2002-2015. PubMed ID: 37738460
[TBL] [Abstract][Full Text] [Related]
14. HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285.
Zhou Z; Zhong L; Chu X; Wan P; Dan W; Shao X; Chen S; Zhang Z; Lu Y; Liu B
Med Oncol; 2023 Oct; 40(11):325. PubMed ID: 37805625
[TBL] [Abstract][Full Text] [Related]
15. MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models.
Fang DD; Tang Q; Kong Y; Rong T; Wang Q; Li N; Fang X; Gu J; Xiong D; Yin Y; Deng J; Yang D; Zhai Y
Cell Death Discov; 2021 May; 7(1):90. PubMed ID: 33941774
[TBL] [Abstract][Full Text] [Related]
16. HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.
Yue K; Sun S; Liu E; Liu J; Hou B; Qi K; Chou CJ; Jiang Y; Li X
Eur J Med Chem; 2024 Feb; 266():116127. PubMed ID: 38224650
[TBL] [Abstract][Full Text] [Related]
17. The role of the MDM2/p53 axis in anti-tumor immune responses.
Brummer T; Zeiser R
Blood; 2023 Jul; ():. PubMed ID: 37467495
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage.
Wang Y; Lin X; Wang Y; Wang G
Invest New Drugs; 2024 Feb; 42(1):70-79. PubMed ID: 38085423
[TBL] [Abstract][Full Text] [Related]
19. Effect of chromatin structure on quantitative ultrasound parameters.
Pasternak M; Doss L; Farhat G; Al-Mahrouki A; Kim CH; Kolios M; Tran WT; Czarnota GJ
Oncotarget; 2017 Mar; 8(12):19631-19644. PubMed ID: 28129644
[TBL] [Abstract][Full Text] [Related]
20. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.
Emadi A; Sadowska M; Carter-Cooper B; Bhatnagar V; van der Merwe I; Levis MJ; Sausville EA; Lapidus RG
Leuk Res; 2015 Jul; 39(7):719-29. PubMed ID: 25982179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
